Email :
Contact : (321) 445-1969

Immunotherapy and Uterine Cancer


Uterine cancer is the most common gynecologic malignancy diagnosed among women in the United States. Globally, the incidence is highest in North America and lowest in South Central Asia. Current standard therapy for uterine cancer most commonly involves surgical removal of the uterus and surrounding tissues along with radiotherapy and chemotherapy depending on the stage of cancer. Sicne patients with advanced or recurrent endometrial cancer have a poor prognosis, there is an urgent need for developing new therapies. Recent developments in the understanding of the etiology and molecular characteritics of uterine cancer has made it possible to explore the role of immunotherapy in treating uterine cancer patients. Currently there are no FDA-approved immunotherapeutic agents available for the treatment of uterine cancer. This review discusses immunotherapy modalities that are under various phases of clinical trial investigations for the treatment of uterine cancer.

Download Pdf